Rotimi Fasimoye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rotimi Fasimoye has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Dairo Renato Alessi
Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK
7 shared publications Dario R Alessi
7 shared publications- Raja Sekhar Nirujogi
MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK
5 shared publications - Berndt Müller
Duke University
3 shared publications - Enrico Bagnoli
Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee
3 shared publications - Esther Sammler
University of Dundee
3 shared publications
Latest Publications
- Open Access
- 22 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 3900-3901
Correction to “Development of BromoTag: A “Bump-and-Hole”–PROTAC System To Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins”
- 22 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 3900-3901
Open AccessCorrection to “Development of BromoTag: A “Bump-and-Hole”–PROTAC System To Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins”
- Open Access
- 26 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
Tagless LysoIP for immunoaffinity enrichment of native lysosomes from clinical samples
Lysosomes are implicated in a wide spectrum of human diseases, including monogenic lysosomal storage disorders (LSDs), age-associated neurodegeneration, and cancer. Profiling lysosomal content using tag-based lysosomal immunoprecipitation (LysoTagIP) in cell and animal models has substantially moved the field forward, but studying lysosomal dysfunction in patients remains challenging. Here, we report the development of the ‘tagless LysoIP’ method, designed to enable the rapid enrichment of lysosomes, via immunoprecipitation, using the endogenous integral lysosomal membrane protein TMEM192, directly from clinical samples and human cell lines (e.g., induced pluripotent stem cell–derived neurons). Isolated lysosomes were intact and suitable for subsequent multimodal omics analyses. To validate our approach, we applied the tagless LysoIP to enrich lysosomes from peripheral blood mononuclear cells derived from fresh blood of healthy donors and patients with CLN3 disease, an autosomal recessive neurodegenerative LSD. Metabolic profiling of isolated lysosomes revealed massive accumulation of glycerophosphodiesters (GPDs) in patients’ lysosomes. Interestingly, a patient with a milder phenotype and genotype displayed lower accumulation of lysosomal GPDs, consistent with their potential role as disease biomarkers. Altogether, the tagless LysoIP provides a framework to study native lysosomes from patient samples, identify disease biomarkers, and discover human-relevant disease mechanisms.
- 26 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
Open AccessTagless LysoIP for immunoaffinity enrichment of native lysosomes from clinical samples
Lysosomes are implicated in a wide spectrum of human diseases, including monogenic lysosomal storage disorders (LSDs), age-associated neurodegeneration, and cancer. Profiling lysosomal content using tag-based lysosomal immunoprecipitation (LysoTagIP) in cell and animal models has substantially moved the field forward, but studying lysosomal dysfunction in patients remains challenging. Here, we report the development of the ‘tagless LysoIP’ method, designed to enable the rapid enrichment of lysosomes, via immunoprecipitation, using the endogenous integral lysosomal membrane protein TMEM192, directly from clinical samples and human cell lines (e.g., induced pluripotent stem cell–derived neurons). Isolated lysosomes were intact and suitable for subsequent multimodal omics analyses. To validate our approach, we applied the tagless LysoIP to enrich lysosomes from peripheral blood mononuclear cells derived from fresh blood of healthy donors and patients with CLN3 disease, an autosomal recessive neurodegenerative LSD. Metabolic profiling of isolated lysosomes revealed massive accumulation of glycerophosphodiesters (GPDs) in patients’ lysosomes. Interestingly, a patient with a milder phenotype and genotype displayed lower accumulation of lysosomal GPDs, consistent with their potential role as disease biomarkers. Altogether, the tagless LysoIP provides a framework to study native lysosomes from patient samples, identify disease biomarkers, and discover human-relevant disease mechanisms.
- Open Access
Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples
Lysosomes are implicated in a wide spectrum of human diseases including monogenic lysosomal storage disorders (LSDs), age-associated neurodegeneration and cancer. Profiling lysosomal content using tag-based lysosomal immunoprecipitation (LysoTagIP) in cell and animal models allowed major discoveries in the field, however studying lysosomal dysfunction in human patients remains challenging. Here, we report the development of the “tagless LysoIP method” to enable rapid enrichment of lysosomes, via immunoprecipitation, using the endogenous integral lysosomal membrane protein TMEM192, directly from clinical samples and human cell lines (e.g. induced Pluripotent Stem Cell (iPSCs) derived neurons). Isolated lysosomes are intact and suitable for subsequent multimodal omics analyses. To validate our approach, we employed the tagless LysoIP to enrich lysosomes from peripheral blood mononuclear cells (PBMCs) derived from fresh blood from patients with CLN3 disease, a neurodegenerative LSD. Metabolic profiling of isolated lysosomes showed massive accumulation of glycerophosphodiesters (GPDs) in patients’ lysosomes. Interestingly, a patient with a milder phenotype and genotype displayed lower accumulation of lysosomal GPDs, consistent with their potential role as disease biomarkers. Altogether, the tagless LysoIP provides a framework to study native lysosomes from patient samples, identify novel biomarkers and discover human-relevant disease mechanisms.
Open AccessTagless LysoIP method for molecular profiling of lysosomal content in clinical samples
Lysosomes are implicated in a wide spectrum of human diseases including monogenic lysosomal storage disorders (LSDs), age-associated neurodegeneration and cancer. Profiling lysosomal content using tag-based lysosomal immunoprecipitation (LysoTagIP) in cell and animal models allowed major discoveries in the field, however studying lysosomal dysfunction in human patients remains challenging. Here, we report the development of the “tagless LysoIP method” to enable rapid enrichment of lysosomes, via immunoprecipitation, using the endogenous integral lysosomal membrane protein TMEM192, directly from clinical samples and human cell lines (e.g. induced Pluripotent Stem Cell (iPSCs) derived neurons). Isolated lysosomes are intact and suitable for subsequent multimodal omics analyses. To validate our approach, we employed the tagless LysoIP to enrich lysosomes from peripheral blood mononuclear cells (PBMCs) derived from fresh blood from patients with CLN3 disease, a neurodegenerative LSD. Metabolic profiling of isolated lysosomes showed massive accumulation of glycerophosphodiesters (GPDs) in patients’ lysosomes. Interestingly, a patient with a milder phenotype and genotype displayed lower accumulation of lysosomal GPDs, consistent with their potential role as disease biomarkers. Altogether, the tagless LysoIP provides a framework to study native lysosomes from patient samples, identify novel biomarkers and discover human-relevant disease mechanisms.
- Open Access
- 27 April 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (12) , 7245-7260
A nematode-specific ribonucleoprotein complex mediates interactions between the major nematode spliced leader snRNP and its target pre-mRNAs
Spliced leader trans-splicing of pre-mRNAs is a critical step in the gene expression of many eukaryotes. How the spliced leader RNA and its target transcripts are brought together to form the trans-spliceosome remains an important unanswered question. Using immunoprecipitation followed by protein analysis via mass spectrometry and RIP-Seq, we show that the nematode-specific proteins, SNA-3 and SUT-1, form a complex with a set of enigmatic non-coding RNAs, the SmY RNAs. Our work redefines the SmY snRNP and shows for the first time that it is essential for nematode viability and is involved in spliced leader trans-splicing. SNA-3 and SUT-1 are associated with the 5′ ends of most, if not all, nascent capped RNA polymerase II transcripts, and they also interact with components of the major nematode spliced leader (SL1) snRNP. We show that depletion of SNA-3 impairs the co-immunoprecipitation between one of the SL1 snRNP components, SNA-2, and several core spliceosomal proteins. We thus propose that the SmY snRNP recruits the SL1 snRNP to the 5′ ends of nascent pre-mRNAs, an instrumental step in the assembly of the trans-spliceosome.
- 27 April 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (12) , 7245-7260
Open AccessA nematode-specific ribonucleoprotein complex mediates interactions between the major nematode spliced leader snRNP and its target pre-mRNAs
Spliced leader trans-splicing of pre-mRNAs is a critical step in the gene expression of many eukaryotes. How the spliced leader RNA and its target transcripts are brought together to form the trans-spliceosome remains an important unanswered question. Using immunoprecipitation followed by protein analysis via mass spectrometry and RIP-Seq, we show that the nematode-specific proteins, SNA-3 and SUT-1, form a complex with a set of enigmatic non-coding RNAs, the SmY RNAs. Our work redefines the SmY snRNP and shows for the first time that it is essential for nematode viability and is involved in spliced leader trans-splicing. SNA-3 and SUT-1 are associated with the 5′ ends of most, if not all, nascent capped RNA polymerase II transcripts, and they also interact with components of the major nematode spliced leader (SL1) snRNP. We show that depletion of SNA-3 impairs the co-immunoprecipitation between one of the SL1 snRNP components, SNA-2, and several core spliceosomal proteins. We thus propose that the SmY snRNP recruits the SL1 snRNP to the 5′ ends of nascent pre-mRNAs, an instrumental step in the assembly of the trans-spliceosome.
- Open Access
- 3 January 2024
- Published by Springer Nature in Research Square
Genetic Associations and Functional Pathways in Parkinson's Disease: A Meta-Analytic Insight into LRRK2 Mutation Impact
Background: Parkinson's Disease (PD) is a complex neurodegenerative disorder with elusive pathophysiological mechanisms. Recent studies have highlighted the role of genetic variations and metabolic changes in PD progression. Aim: This study aims to investigate the genetic disparities in PD, particularly focusing on LRRK2 mutations, and to analyze the associated metabolic pathway alterations. Methodology: The study utilized R programming with MetaIntegrator for meta-analysis and ggplot2 for visualization. Datasets underwent preprocessing, and the MetaIntegrator package computed meta scores, effects, and ROC analysis. Differential gene expression and functional enrichment analyses provided insights into genetic associations and pathways in Parkinson's disease and LRRK2 mutations. Results: Significant meta-score differences were observed in PD patients, especially in datasets GSE133347, GSE36321, and GSE100054, underscoring the impact of LRRK2 mutations. Genes like SKAP2 and IFNGR2 were significantly upregulated, implicating their role in neuroinflammation. Moreover, a shift in metabolic pathways, particularly carbohydrate kinase activity, was noted, indicating altered energy metabolism in PD cells. Conclusion: The study reinforces the genetic heterogeneity of PD and highlights the potential therapeutic importance of targeting neuroinflammatory pathways and metabolic dysfunctions. These findings suggest new avenues for diagnostic and therapeutic strategies in PD management.
- 3 January 2024
- Published by Springer Nature in Research Square
Open AccessGenetic Associations and Functional Pathways in Parkinson's Disease: A Meta-Analytic Insight into LRRK2 Mutation Impact
Background: Parkinson's Disease (PD) is a complex neurodegenerative disorder with elusive pathophysiological mechanisms. Recent studies have highlighted the role of genetic variations and metabolic changes in PD progression. Aim: This study aims to investigate the genetic disparities in PD, particularly focusing on LRRK2 mutations, and to analyze the associated metabolic pathway alterations. Methodology: The study utilized R programming with MetaIntegrator for meta-analysis and ggplot2 for visualization. Datasets underwent preprocessing, and the MetaIntegrator package computed meta scores, effects, and ROC analysis. Differential gene expression and functional enrichment analyses provided insights into genetic associations and pathways in Parkinson's disease and LRRK2 mutations. Results: Significant meta-score differences were observed in PD patients, especially in datasets GSE133347, GSE36321, and GSE100054, underscoring the impact of LRRK2 mutations. Genes like SKAP2 and IFNGR2 were significantly upregulated, implicating their role in neuroinflammation. Moreover, a shift in metabolic pathways, particularly carbohydrate kinase activity, was noted, indicating altered energy metabolism in PD cells. Conclusion: The study reinforces the genetic heterogeneity of PD and highlights the potential therapeutic importance of targeting neuroinflammatory pathways and metabolic dysfunctions. These findings suggest new avenues for diagnostic and therapeutic strategies in PD management.
- Open Access
- 15 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (50) , eadj1205
Parkinson’s VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B
We demonstrate that the Parkinson’s VPS35[D620N] mutation alters the expression of ~220 lysosomal proteins and stimulates recruitment and phosphorylation of Rab proteins at the lysosome. This recruits the phospho-Rab effector protein RILPL1 to the lysosome where it binds to the lysosomal integral membrane protein TMEM55B. We identify highly conserved regions of RILPL1 and TMEM55B that interact and design mutations that block binding. In mouse fibroblasts, brain, and lung, we demonstrate that the VPS35[D620N] mutation reduces RILPL1 levels, in a manner reversed by LRRK2 inhibition and proteasome inhibitors. Knockout of RILPL1 enhances phosphorylation of Rab substrates, and knockout of TMEM55B increases RILPL1 levels. The lysosomotropic agent LLOMe also induced LRRK2 kinase–mediated association of RILPL1 to the lysosome, but to a lower extent than the D620N mutation. Our study uncovers a pathway through which dysfunctional lysosomes resulting from the VPS35[D620N] mutation recruit and activate LRRK2 on the lysosomal surface, driving assembly of the RILPL1-TMEM55B complex.
- 15 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (50) , eadj1205
Open AccessParkinson’s VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B
We demonstrate that the Parkinson’s VPS35[D620N] mutation alters the expression of ~220 lysosomal proteins and stimulates recruitment and phosphorylation of Rab proteins at the lysosome. This recruits the phospho-Rab effector protein RILPL1 to the lysosome where it binds to the lysosomal integral membrane protein TMEM55B. We identify highly conserved regions of RILPL1 and TMEM55B that interact and design mutations that block binding. In mouse fibroblasts, brain, and lung, we demonstrate that the VPS35[D620N] mutation reduces RILPL1 levels, in a manner reversed by LRRK2 inhibition and proteasome inhibitors. Knockout of RILPL1 enhances phosphorylation of Rab substrates, and knockout of TMEM55B increases RILPL1 levels. The lysosomotropic agent LLOMe also induced LRRK2 kinase–mediated association of RILPL1 to the lysosome, but to a lower extent than the D620N mutation. Our study uncovers a pathway through which dysfunctional lysosomes resulting from the VPS35[D620N] mutation recruit and activate LRRK2 on the lysosomal surface, driving assembly of the RILPL1-TMEM55B complex.
- Open Access
- 8 May 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (20)
Golgi-IP, a tool for multimodal analysis of Golgi molecular content
The Golgi is a membrane-bound organelle that is essential for protein and lipid biosynthesis. It represents a central trafficking hub that sorts proteins and lipids to various destinations or for secretion from the cell. The Golgi has emerged as a docking platform for cellular signaling pathways including LRRK2 kinase whose deregulation leads to Parkinson disease. Golgi dysfunction is associated with a broad spectrum of diseases including cancer, neurodegeneration, and cardiovascular diseases. To allow the study of the Golgi at high resolution, we report a rapid Golgi immunoprecipitation technique (Golgi-IP) to isolate intact Golgi mini-stacks for subsequent analysis of their content. By fusing the Golgi-resident protein TMEM115 to three tandem HA epitopes (GolgiTAG), we purified the Golgi using Golgi-IP with minimal contamination from other compartments. We then established an analysis pipeline using liquid chromatography coupled with mass spectrometry to characterize the human Golgi proteome, metabolome, and lipidome. Subcellular proteomics confirmed known Golgi proteins and identified proteins not previously associated with the Golgi. Metabolite profiling established the human Golgi metabolome and revealed the enrichment of uridine-diphosphate (UDP) sugars and their derivatives, which is consistent with their roles in protein and lipid glycosylation. Furthermore, targeted metabolomics validated SLC35A2 as the subcellular transporter for UDP-hexose. Finally, lipidomics analysis showed that phospholipids including phosphatidylcholine, phosphatidylinositol, and phosphatidylserine are the most abundant Golgi lipids and that glycosphingolipids are enriched in this compartment. Altogether, our work establishes a comprehensive molecular map of the human Golgi and provides a powerful method to study the Golgi with high precision in health and disease.
- 8 May 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (20)
Open AccessGolgi-IP, a tool for multimodal analysis of Golgi molecular content
The Golgi is a membrane-bound organelle that is essential for protein and lipid biosynthesis. It represents a central trafficking hub that sorts proteins and lipids to various destinations or for secretion from the cell. The Golgi has emerged as a docking platform for cellular signaling pathways including LRRK2 kinase whose deregulation leads to Parkinson disease. Golgi dysfunction is associated with a broad spectrum of diseases including cancer, neurodegeneration, and cardiovascular diseases. To allow the study of the Golgi at high resolution, we report a rapid Golgi immunoprecipitation technique (Golgi-IP) to isolate intact Golgi mini-stacks for subsequent analysis of their content. By fusing the Golgi-resident protein TMEM115 to three tandem HA epitopes (GolgiTAG), we purified the Golgi using Golgi-IP with minimal contamination from other compartments. We then established an analysis pipeline using liquid chromatography coupled with mass spectrometry to characterize the human Golgi proteome, metabolome, and lipidome. Subcellular proteomics confirmed known Golgi proteins and identified proteins not previously associated with the Golgi. Metabolite profiling established the human Golgi metabolome and revealed the enrichment of uridine-diphosphate (UDP) sugars and their derivatives, which is consistent with their roles in protein and lipid glycosylation. Furthermore, targeted metabolomics validated SLC35A2 as the subcellular transporter for UDP-hexose. Finally, lipidomics analysis showed that phospholipids including phosphatidylcholine, phosphatidylinositol, and phosphatidylserine are the most abundant Golgi lipids and that glycosphingolipids are enriched in this compartment. Altogether, our work establishes a comprehensive molecular map of the human Golgi and provides a powerful method to study the Golgi with high precision in health and disease.
- Open Access
- 5 May 2023
- Published by Springer Nature
Organelle isolation from mouse tissues expressing organelle tags v1
We describe here a method to perform the rapid isolation of intact lysosomes from mouse tissues expressing a lysosome-localized TMEM192-3×HA fusion protein (“LysoTag”) (as in JAX stock #035401, RRID:IMSR_JAX:035401). The fusion protein marks lysosomes with a triple HA epitope, enabling the rapid isolation of intact tagged organelles from tissues using an anti-HA antibody. The organelles purified using this method are highly enriched, intact, largely contaminant-free and can be used for various downstream applications, including immunoblotting analysis and proteomic analysis (as described in dx.doi.org/10.17504/protocols.io.ewov1o627lr2/v1), but also lipidomic or metabolomic analysis (as described in dx.doi.org/10.17504/protocols.io.bybjpskn). This method can be adapted to isolate other tagged organelles from tissues.
- 5 May 2023
- Published by Springer Nature
Open AccessOrganelle isolation from mouse tissues expressing organelle tags v1
We describe here a method to perform the rapid isolation of intact lysosomes from mouse tissues expressing a lysosome-localized TMEM192-3×HA fusion protein (“LysoTag”) (as in JAX stock #035401, RRID:IMSR_JAX:035401). The fusion protein marks lysosomes with a triple HA epitope, enabling the rapid isolation of intact tagged organelles from tissues using an anti-HA antibody. The organelles purified using this method are highly enriched, intact, largely contaminant-free and can be used for various downstream applications, including immunoblotting analysis and proteomic analysis (as described in dx.doi.org/10.17504/protocols.io.ewov1o627lr2/v1), but also lipidomic or metabolomic analysis (as described in dx.doi.org/10.17504/protocols.io.bybjpskn). This method can be adapted to isolate other tagged organelles from tissues.
- Open Access
- 22 August 2022
- Published by Springer Nature
Preparation and imaging of enriched Golgi from GolgiTAG-IP using Transmission Electron Microscopy v1
Transmission electron microscopy (TEM) is a tool used to image, in good resolution, the structure of organelles within the cell. Available protocols are designed to image structures within fixed intact cells. Here, we described a protocol where Golgi, isolated from cells by GolgiTAG immunoprecipitation (IP) (as described in ddx.doi.org/10.17504/protocols.io.6qpvrdjrogmk/v1), can be prepared and imaged using TEM. This protocol can also be used to image any organelles isolated using various organelle-IP protocols that are available.
- 22 August 2022
- Published by Springer Nature
Open AccessPreparation and imaging of enriched Golgi from GolgiTAG-IP using Transmission Electron Microscopy v1
Transmission electron microscopy (TEM) is a tool used to image, in good resolution, the structure of organelles within the cell. Available protocols are designed to image structures within fixed intact cells. Here, we described a protocol where Golgi, isolated from cells by GolgiTAG immunoprecipitation (IP) (as described in ddx.doi.org/10.17504/protocols.io.6qpvrdjrogmk/v1), can be prepared and imaged using TEM. This protocol can also be used to image any organelles isolated using various organelle-IP protocols that are available.
- Open Access
- 18 August 2022
- Published by Springer Nature
Protocol for Data Independent Acquisition - Mass spectrometry analysis – a DIA-based Organelle Proteomics v1
Purification of intact organelles by previously described methods (dx.doi.org/10.17504/protocols.io.bybjpskn; dx.doi.org/10.17504/protocols.io.6qpvrdjrogmk/v1) allows to profile the organelle proteome using quantitative mass spectrometry. Here we provide a detailed protocol for the Data Independent Acquisition (DIA)-based mass spectrometry (MS) data acquisition method for proteomic profiling of the Golgi. This includes a description of how to construct the nano Liquid chromatography and DIA MS methods as well as a Data Dependent Acquisition (DDA) strategy to generate deep spectral libraries to be able to use in searching the DIA data. In addition, we provide detailed search parameters for database search for both DDA and DIA and downstream MS data analysis.
- 18 August 2022
- Published by Springer Nature
Open AccessProtocol for Data Independent Acquisition - Mass spectrometry analysis – a DIA-based Organelle Proteomics v1
Purification of intact organelles by previously described methods (dx.doi.org/10.17504/protocols.io.bybjpskn; dx.doi.org/10.17504/protocols.io.6qpvrdjrogmk/v1) allows to profile the organelle proteome using quantitative mass spectrometry. Here we provide a detailed protocol for the Data Independent Acquisition (DIA)-based mass spectrometry (MS) data acquisition method for proteomic profiling of the Golgi. This includes a description of how to construct the nano Liquid chromatography and DIA MS methods as well as a Data Dependent Acquisition (DDA) strategy to generate deep spectral libraries to be able to use in searching the DIA data. In addition, we provide detailed search parameters for database search for both DDA and DIA and downstream MS data analysis.